ALSO NOTED: Rituxan aces RA, leukemia trials; Two die after Gardasil jab; Galapagos earns milestone; and much more...

> Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult leukemia. Release

> Two young women died suddenly and mysteriously after getting the Gardasil vaccine, European regulators announced yesterday. Did the vaccine precipitate their deaths? No one knows. Report

> Galapagos has achieved a milestone under its alliance agreement in rheumatoid arthritis with Johnson & Johnson's Janssen Pharmaceutica. The milestone triggered a cash payment of €3.4 million to Galapagos. Release

> Lawyers, Congressional reps, and now Senators are circling around Merck and Schering-Plough as the Vytorin brouhaha escalates into a full-blown scandal. Report

> A small clinical trial of a malaria vaccine funded by the National Institute of Allergy and Infectious Diseases has delivered positive data, triggering a move to expand the research into a second trial that enlisted 400 children in Mali. Report

> Health plans are drawing scrutiny for paying physicians to prescribe cheaper generics rather than brand-name drugs. Report

And Finally... American adults are largely ignoring a slate of important new vaccines that can prevent serious illness, according to a new survey from the National Foundation for Infectious Diseases. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.